-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
4D Molecular Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2024.
- 4D Molecular Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$51.1M, a 266% decline year-over-year.
- 4D Molecular Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$168M, a 60.5% decline year-over-year.
- 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$113M, a 2.58% decline from 2022.
- 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$110M, a 54.3% decline from 2021.
- 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$71.3M, a 25.9% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)